Sequenom Shares Climb Again | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of Sequenom rose around 20 percent for the second straight day after the firm reported yesterday that a blinded study showed that its molecular test for Down syndrome correctly identified 100 percent of all Down syndrome samples without any false-positive outcomes.
 
That announcement pushed Sequenom’s shares up 22 percent yesterday.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.